pioglitazone has been researched along with drf 2725 in 7 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (71.43) | 29.6817 |
2010's | 2 (28.57) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Andersen, AS; Brand, CL; Bury, PS; Fleckner, J; Jeppesen, L; Lehmann, SV; Mogensen, JP; Mortensen, SB; Panajotova, V; Pettersson, I; Polivka, Z; Rasmussen, HB; Sauerberg, P; Sindelar, K; Sturis, J; Svensson, LA; Wassermann, K; Wöldike, HF; Wulff, EM; Ynddal, L | 1 |
Deussen, HJ; Ebdrup, S; Fleckner, J; Frost Jensen, A; Mortensen, SB; Nygaard, L; Pettersson, I; Pridal, L; Rasmussen, HB; Sauerberg, P | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Jensen, PB; Larsen, LK; Larsen, PJ; Sørensen, RV; Vrang, N; Wassermann, K; Wulff, EM | 1 |
Cai, ZF; Guo, ZR | 1 |
Brand, CL; Pickavance, LC; Wassermann, K; Wilding, JP | 1 |
1 review(s) available for pioglitazone and drf 2725
Article | Year |
---|---|
[Peroxisome poliferator-activated receptors and their modulators].
Topics: Animals; Humans; Oxazines; Phenylpropionates; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors | 2004 |
6 other study(ies) available for pioglitazone and drf 2725
Article | Year |
---|---|
Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity.
Topics: Animals; Blood Glucose; Carbazoles; Cholesterol; Cholesterol, Dietary; Crystallography, X-Ray; Drug Evaluation, Preclinical; Glucose Tolerance Test; Hypoglycemic Agents; Hypolipidemic Agents; Male; Mice; Models, Molecular; Nuclear Proteins; Phenylpropionates; Pioglitazone; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Stereoisomerism; Structure-Activity Relationship; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides | 2002 |
Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist ragaglitazar.
Topics: Binding Sites; Crystallography, X-Ray; Hypoglycemic Agents; Ligands; Models, Molecular; Oxazines; Phenylpropionates; Radioligand Assay; Receptors, Cytoplasmic and Nuclear; Stereoisomerism; Transcription Factors | 2003 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Differential influences of peroxisome proliferator-activated receptors gamma and -alpha on food intake and energy homeostasis.
Topics: Adipose Tissue; Animals; Biomarkers; Blood Glucose; Eating; Energy Metabolism; Fenofibrate; Gene Expression; Glucose Tolerance Test; Glycated Hemoglobin; Homeostasis; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Lipids; Liver; Male; Obesity; Organ Size; Oxazines; Phenylpropionates; Pioglitazone; Rats; Rats, Mutant Strains; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Weight Gain | 2003 |
The dual PPARalpha/gamma agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats.
Topics: Adipose Tissue; Animals; Bezafibrate; Body Composition; Body Weight; Diabetes Mellitus; Diet; Energy Metabolism; Glucose Clamp Technique; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Insulin Resistance; Obesity; Organ Size; Oxazines; Pancreas; Phenylpropionates; Pioglitazone; PPAR alpha; PPAR gamma; Rats; Rats, Inbred Strains; Receptors, Cell Surface; Receptors, Leptin; Thiazolidinediones | 2005 |